Medical Advocates
Efavirenz (Sustiva/Strocrin)
 
Pediatric Data

General Reports
 Pharmacokinetics
 Viral Dynamics
Adverse Events
Monitoring
 Efficacy
Treatment Strategies
 US Treatment Guidelines


 
Main New/Newsworthy Home Page      
Last Update:  February 28, 2010
 Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader
General Reports
 

Journal Papers, Abstracts, and Commentaries

 
Efavirenz-loaded polymeric micelles for pediatric anti-HIV pharmacotherapy with
significantly higher oral bioavailaibility.
 Chiappetta DA, Hocht C, Taira C, Sosnik A.
Nanomed. 2010 Jan;5(1):11-23
 Abstract

Are recommended dose of efavirenz optimal in young West African HIV-infected children?
(ANRS 12103).
Hirt D, Urien S, Olivier M, Peyrière H, et al
 Antimicrob Agents Chemother. 2009 Jul 27
Abstract

High Prevalence of Subtherapeutic Plasma Concentrations of Efavirenz in Children.
 Ren Y, Nuttall JJ, Egbers C, et al  
J Acquir Immune Defic Syndr. 2007 Apr 5;
Abstract
 
Conference Reports, Abstracts, and Posters
 
  Efavirenz Plasma Concentrations and the Association with CYP2B6-516 T Polymorphism in HIV-infected
Thai Children
 T Puthanakit, P Tanpaiboon, L Aurpibul, et al
 (16 CROI)
 Abstract
Pharmacokinetics
 
Journal Papers, Abstracts, and Commentaries
 
 
A pharmacokinetic and pharmacogenetic study of efavirenz in children: dosing guidelines can result in
subtherapeutic concentrations.
ter Heine R, Scherpbier HJ, Crommentuyn KM, et al
Antivir Ther. 2008;13(6):779-8
 Abstract

Pharmacokinetics and Pharmacodynamics of Efavirenz and Nelfinavir in HIV-infected Children
Participating in an Area-under-the-curve Controlled Trial.
 Fletcher CV, Brundage RC, Fenton T, et al 
Clin Pharmacol Ther. 2007 Jul 4;
Abstract

Conference Reports, Abstracts, and Posters

 
POSTER
 Pharmacokinetics of Efavirenz Dosed According to the WHO Weight-bands in Children in Uganda
 S Bakeera-Kitaka, E Natukunda, L Kendall, et al
 (17CROI)
PDF Poster     Abstract

POSTER
 Age-related Pharmacokinetics of Efavirenz Solution
 E Capparelli, M Rochon-Duck, B Robbins,  et al
 (16 CROI)
PDF Poster     Abstract

 Abstract

CYP2B6-G516T Polymorphisms Influence Plasma Concentrations of Efavirenz in HIV-
1-infected Children Receiving HAART
 A Saitoh, C Fletcher, R Brundage, et al
(13  CROI)
 Abstract
Viral Dynamics
 

Journal Papers, Abstracts, Letters, and Commentaries

  Patterns of plasma human immunodeficiency virus type 1 RNA response to
highly active antiretroviral therapy in infected children.
Spector SA, Yong FH, Cabral S et al.
Journal of Infectious Disease 2000; 182(6): 1769-1773.
Abstract
Adverse Events
 

Journal Papers, Abstracts, Letters, and Commentaries

  Psychosis in a 12-year-old HIV-positive girl with an increased serum concentration of efavirenz.
 Lowenhaupt EA, Matson K, Qureishi B,et al  
Clin Infect Dis. 2007 Nov 15;45(10):e128-30.
Abstract

 
Conference Reports, Abstracts, and Posters
 
( POSTER
 2-Year Evolution of Triglycerides and Cholesterol in Thai HIV-1-infected Children Receiving
First-line NVP or Efavirenz EFV-based Regimen
S Kanjanavanit, R Hansudewechakul, S Kim, et al
(17th CROI)
PDF Poster     Abstract
Efficacy
 
Journal Papers, Abstracts, Letters, and Commentaries
 
Efficacy and tolerability of nevirapine- versus efavirenz-containing regimens in HIV-infected Thai children.
 Lapphra K, Vanprapar N, Chearskul S, et al
Int J Infect Dis. 2008 Jun 21.
 Abstract
 
Antiviral efficacy, tolerability and pharmacokinetics of efavirenz in an unselected cohort of
HIV-infected children.
 Wintergerst U, Hoffmann F, Jansson A, et al 
J Antimicrob Chemother. 2008 Mar 13
Abstract
 
Once-Daily Highly Active Antiretroviral Therapy for HIV-Infected Children: Safety and Efficacy
of an Efavirenz-Containing Regimen.
 Scherpbier HJ, Bekker V, Pajkrt D, et al 
Pediatrics. 2007 Feb 16;
 Abstract
 
A WEEK-IN-REVIEW FEATURED REPORT
Effect of First Line Therapy Including Efavirenz and Two Nucleoside Reverse Transcriptase
Inhibitors in HIV-infected Children.
 Funk MB, Notheis G, Schuster T, et al 
Eur J Med Res. 2005 Dec 7;10(12):503-8.
 Abstract
 
Safety and efficacy of a NRTI-sparing HAART regimen of efavirenz and
lopinavir/ritonavir in HIV-1-infected children.
 Fraaij PL, Neubert J, Bergshoeff AS
Antivir Ther. 2004 Apr;9(2):297-9
 Letter

FULL-TEXT ARTICLE
Impact of Protease Inhibitor Substitution With Efavirenz in HIV-Infected Children:
Results of the First Pediatric Switch Study.
McComsey G, Bhumbra N, Ma JF, et al 
Pediatrics 2003 Mar;111(3):E275-E281
Paper

Combination therapy with efavirenz, nelfinavir, and nucleoside reverse- transcriptase
inhibitors in children infected with human immunodeficiency virus type 1.
Pediatric AIDS Clinical Trials Group 382 Team. Starr SE, Fletcher CV, et al.
New England Journal of Medicine 1999; 341(25): 1874-881.
Abstract
 

  
Conference Reports, Abstracts, and Posters
 
 
Are Recommended Dosages of Efavirenz Optimal in Young Children? ANRS 12103
 D Hirt, S Urien, M Olivier, et al
 (16CROI)
 Abstract
POWERPOINT POSTER PRESENTATION
Once-a-day pediatric HAART with DDI+3TC+EFV in Burkina Faso - a phase II Trial
(ANRS 12103 trial)
 P. Msellati
(XVII International AIDS Conference)
 Poster  Presentation
 
Long-term effectiveness of NNRTI-based HAART in antiretroviral-naive HIV-infected children
participating in Thailand´s National Access Program: 192-week result
Aurpibul L, Puthanakit T, Oberdorfer P, et al
 (4th IAS Conference)
 Abstract
 
TREC Response in P1021: A Once-daily Regimen of Emtricitabine, Didanosine, and Efavirenz
in Previously Naive Children
R Dickover, D Smith, P Britto, et al
 (13 CROI)
 Abstract

Potency of efavirenz as part of a first-line antiretroviral therapy (ART) regimen in antiretroviral naïve
children in a public hospital in Soweto, South Africa
T  Meyers, HJ  Moultrie, S Mtshizana, H Gous
 (15IAC)
 Abstract
 
  Effect of first line therapy including efavirenz and two nucleoside reverse transcriptase inhibitors
in previously untreated HIV-infected children
MB Funk, Z Elanjikal, G Notheis,  et al
 (15IAC)
Antiretroviral efficacy and tolerability of Abacavir (ABC) based regimens in a clinical cohort of
HIV-infected children
 F Hoffmann, T Niehues, B Buchholz, et al
 (14IAC)
 Abstract
Monitoring
 
Conference Reports, Abstracts, and Posters
 
 
Exploring the feasibility of dried blood spots for quantification of lopinavir, nevirapine and efavirenz
concentrations
L Else, L Dickinson, M Schellenberger, et al
 (8th Int Congress on Drug Therapy in HIV Infection )
 Abstract

TDM of efavirenz as a tool of adherence in HIV-infected children
 R Rosso, A Di Biagio, C Dentone, et al
(8th Int Congress on Drug Therapy in HIV Infection )
 Abstract
Treatment Strategies
 

Switching Therapies

Conference Reports, Abstracts, and Posters

  Switching Stavudine to Tenofovir and Protease Inhibitor to Efavirenz  Results in a
Favorable Clinical Outcome in HIV-infected Children
 A Viganò , V Giacomet , S Beretta , et al
(!2  CROI)
 Abstract
 
HIV/TB Coinfection
 
Journal Papers, Abstracts, Letters, and Commentaries
 
  Effect of Rifampicin on Efavirenz Pharmacokinetics in HIV-Infected Children With Tuberculosis.
 Ren Y, Nuttall JJ, Eley BS, et al
J Acquir Immune Defic Syndr. 2009 Feb 13.
 Abstract

Conference Reports, Abstracts, and Posters
 
  Plasma Concentrations of Efavirenz and Lopinavir in Children with and without Rifampicin-
based Anti-TB Treatment
 Y Ren, J Nuttall, C Egbers, et al
 (!4  CROI)
 Abstract

Main New/Newsworthy Home Page      

 Efavirenz Pediatric Data